Clinical Trial Update: A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation [Phase 3]

View source ↗

Summary

Phase 3 study evaluating safety of the inhaled COPD therapy QVA149 versus QAB149 over 52 weeks; the trial is completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• QAB149
• QVA149 (indacaterol/glycopyrronium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2016-03-30